Clinical trials: Diabetes Type 2
Obesity
Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM
This was a multi-center, randomized, placebo-controlled, participant-and-investigator-blinded, sponsor open-label study in obese participants with or without Type 2 Diabetes Mellitus.
- Trial name
- NCT05199090
- Testing
- MBL949
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking metformin for type 2 diabetes.
- Trial name
- NCT00792935
- Testing
- MK-0941, Glimepiride, Metformin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus…
- Trial name
- NCT02648217
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart
- Where
- 32 sites in Algeria, India and 4 more
- Volunteers
- 263 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)
This study aims to randomly assign individuals with type 2 diabetes into the ENHANCED randomized control trial. The study is being conducted by the Minneapolis Heart Institute Foundation (MHIF) and will have two study sites 1)…
- Trial name
- ENHANCED (NCT02980978)
- Testing
- Coaching
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Minneapolis Heart Institute Foundation
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with…
- Trial name
- NCT00612040
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effectiveness of basal insulin analog and insulin analog mid mixture in Chinese participants with type 2 diabetes mellitus.
- Trial name
- CLASSIC (NCT03018938)
- Testing
- Insulin Analog Mid Mixture, Basal Insulin Analog
- Where
- 32 sites in China
- Volunteers
- 814 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Treated With Insulin
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains…
- Trial name
- In-FI (NCT04460326)
- Testing
- Insulin glargine, NovoLog, Insulin Fiasp
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Boston Medical Center
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of TA-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days).
- Trial name
- NCT00707954
- Testing
- TA-7284
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India
The purpose of the India iPro2 study is to demonstrate that iPro2 Continuous Glucose Monitoring System (CGMS) evaluation enables Health Care Professional (HCP)s treating patients in India with type 2 diabetes to get a better…
- Trial name
- NCT01995539
- Testing
- therapy regimen
- Where
- 11 sites in India
- Volunteers
- 181 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
The objective of this study is to identify EMR-based clinical covariates and quantify their association with the prescribing of each specific type 2 diabetes (T2DM) medication under investigation.
- Trial name
- NCT02140645
- Testing
- linagliptin
- Where
- United States
- Volunteers
- 166,613 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).
- Trial name
- NCT03362112
- Volunteers
- 1,713 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels.
- Trial name
- NCT02703337
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Heart Failure, Diabetes Mellitus, Type 2
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
This is a randomized trial of the addition of dapagliflozin to patients with or without type 2 diabetes hospitalized with acute decompensated heart failure (ADHF).
- Trial name
- DICTATE-AHF (NCT04298229)
- Testing
- Dapagliflozin 10 MG, Protocolized Diuretic Therapy
- Where
- 6 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Mellitus, Type 2
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US)…
- Trial name
- NCT02750930
- Testing
- Albiglutide, Auto-injector
- Where
- 27 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
- Trial name
- SURPASS-2 (NCT03987919)
- Testing
- Tirzepatide, Semaglutide
- Where
- 127 sites in United States, Argentina and 7 more
- Volunteers
- 1,879 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate…
- Trial name
- NCT02154347
- Testing
- KAD-1229, Insulin
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.
- Trial name
- NCT01512849
- Testing
- TA-7284 Low, TA-7284 High
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Tanabe Pharma Corporation
Fatty Liver
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver disease in developed countries.
- Trial name
- NCT00323414
- Testing
- Polyunsaturated fatty acid (Opti-EPA)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.